A PHASE 3, DOUBLE-BLINDED, VEHICLE-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF TWICE DAILY DELGOCITINIB CREAM IN ADULT PARTICIPANTS WITH LICHEN SCLEROSUS DURING A 12-WEEK INITIAL TREATMENT PERIOD FOLLOWED BY A 40-WEEK CONTINUATION TREATMENT PERIOD

Registry ID

LP0133-2395

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

LEO PHARMA AS

Start date

2026-05-08

Last update

2026-04-14

Conditions

• LICHEN SCLEROSUS

View on source registry